ViroGates A/S (VIRO)

Overview

ViroGates A/S is a pioneering in vitro diagnostics company that has made significant strides in developing and marketing prognostic products designed to enhance decision-making in the healthcare sector. The company leverages its proprietary biomarker, suPARnostic, to provide valuable insights for hospital emergency services. This innovative tool aids in crucial decisions regarding the hospitalization or discharge of acute patients and plays a key role in the early identification of patients at high-risk of developing sepsis. Beyond emergency and critical care settings, suPARnostic finds applications in assessing the prognosis of lifestyle-related diseases, including cardiovascular disease, type 2 diabetes, and cancer. Moreover, it offers a novel approach for evaluating longevity and biological age in non-hospital settings. Founded in the year 2000 and based in Birkerød, Denmark, ViroGates A/S is dedicated to offering cutting-edge solutions that enhance patient care and outcomes.

Products and Services

• suPARnostic TurbiLatex: A latex particle-enhanced turbidimetric immunoassay designed for the quantitative determination of the soluble urokinase plasminogen activator receptor (suPAR) levels in human K2-EDTA- or lithium heparin plasma samples. This product stands out for its precision in quantifying suPAR levels, facilitating accurate prognosis and monitoring in various medical conditions.
• suPARnostic ELISA: Known for providing fully quantitative results, the suPARnostic ELISA kit is indispensable for laboratories requiring detailed analysis and accurate quantification of suPAR levels in blood plasma. It is crucial for research and clinical settings where precise measurements are essential for patient care.
• suPARnostic Quick Triage: A rapid, point-of-care test kit designed for early warning and patient triaging. It enables clinicians and nurses to quickly assess the severity, progression, and potential outcomes of patient diseases, making it a valuable tool in emergency departments and other acute care settings.
• suPARnostic POC+: This point-of-care test is designed for ease of use, allowing for the detection of suPAR levels through a simple finger prick. It's particularly beneficial for settings where immediate results are critical for decision-making, including initial patient assessment and monitoring in non-hospital settings. The POC+ enhances accessibility to vital prognostic information, improving patient management and care pathways.